MedDataX Logo

Boosting Microbiota Butyrate Producers to Improve Gut Health

NCT ID: NCT07198984

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-24

Study Completion Date

2028-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The human gut microbiota is a dynamic ecosystem essential to health, influenced by diet, age, and lifestyle. It plays a key role in digestion, immunity, and nervous system regulation. Among its important compounds, short-chain fatty acids, particularly butyrate, are crucial for intestinal and metabolic balance, as they support homeostasis, strengthen the epithelial barrier, and have anti-inflammatory effects.

An imbalance in the microbiota, especially a decrease in butyrate-producing bacteria, is linked to intestinal, metabolic, and neurological disorders. A fiber-rich diet promotes the growth of these beneficial bacteria.

This study aims to isolate and characterize probiotics that can enhance butyrate production, thereby improving intestinal health and microbiota balance. Sampling conditions will comply with regulations governing research involving human subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The human gut microbiota is a complex and adaptable ecosystem closely linked to its host, influenced by factors such as diet, lifestyle, and age. It plays key roles in nutrition, immunity, and pathogen protection by breaking down otherwise indigestible fibers into short-chain fatty acids, which are essential for energy production, metabolism, and immune balance.

Butyrate, the best-studied short-chain fatty acids, provides most of the energy for colonic cells, strengthens the intestinal barrier, reduces inflammation, and regulates gene expression related to cell growth, apoptosis, and autophagy. A decrease in butyrate-producing bacteria has been associated with intestinal, metabolic, neurological, and other diseases, including rheumatoid arthritis and fatty liver disease.

Maintaining a healthy microbiota-particularly through a fiber-rich diet that supports butyrate producers-is essential for digestion, nutrient absorption, immune regulation, and overall health, highlighting the strategic role of butyrate in disease prevention and well-being.

This project hypothesizes that increasing microbiota-derived butyrate could improve gut health. Its aim is to isolate and characterize probiotic strains capable of boosting butyrate production, in order to develop scientifically grounded, high-functionality probiotic products. The study will also assess whether butyrate production correlates with beneficial in vitro effects and further clarify how butyrate producers interact with both the microbiota and the host.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adults 20 to 80 Years

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* People between the ages of 20 and 80, in good health, with a body mass index between 18.5 kg/m² and 30 kg/m², who are not deprived of their liberty or under guardianship.
* Additional criteria for people aged between 20 and 60: Engaging in sports at least twice a week or following a flexitarian diet, No known chronic conditions, Not undergoing chronic treatment.

Exclusion Criteria

* Under the age of 20 or over the age of 80, Part of the principal investigator's team, Reporting to the investigator (intern, student, or employee under their authority), Having been on antibiotic therapy in the 3 months prior to sampling, Having taken probiotics in the 15 days prior to sampling, Having taken synbiotics in the 15 days prior to sampling, Having a BMI below 18.5 kg/m² or above 30 kg/m², Being deprived of liberty or under guardianship.
* Additional criteria for people aged between 20 and 60: Not exercising twice a week or following a flexitarian diet, Having a chronic illness, Undergoing chronic treatment
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

INRAE

Jouy-en-Josas, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

REBECA MARTIN ROSIQUE, PhD

Role: CONTACT

[email protected]
00 33 1 34 65 20 98

ELISE BOREZEE, PhD

Role: CONTACT

[email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

REBECA MARTIN ROSIQUE, PhD

Role: primary

[email protected]
00 33 1 34 65 20 98

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-00623-46

Identifier Type: -

Identifier Source: org_study_id